DEVELOPMENT OF A TISSUE-ENGINEERED VASCULAR GRAFT

Information

  • Research Project
  • 6015691
  • ApplicationId
    6015691
  • Core Project Number
    R43HL063544
  • Full Project Number
    1R43HL063544-01
  • Serial Number
    63544
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/30/1999 - 25 years ago
  • Project End Date
    3/29/2000 - 24 years ago
  • Program Officer Name
  • Budget Start Date
    9/30/1999 - 25 years ago
  • Budget End Date
    3/29/2000 - 24 years ago
  • Fiscal Year
    1999
  • Support Year
    1
  • Suffix
  • Award Notice Date
    9/28/1999 - 25 years ago
Organizations

DEVELOPMENT OF A TISSUE-ENGINEERED VASCULAR GRAFT

The development of a non-occluding, small diameter (4 mm or less) prosthetic vascular graft has been the focus of extensive research by scientists, clinicians and engineers. Although a variety of synthetic materials have been successful in applications requiring large diameter grafts, only autologous vessels provide clinically acceptable function for smaller grafts such as are required for coronary artery bypass surgery. The need to harvest autologous vessels increases the morbidity and costs associated with bypass procedures and, in some cases, patients do not suitable vessels available. The research outlined in this proposal will evaluate the use of a prosthetic vascular graft constructed from a biologically-derived collagen material. This intestinal collagen layer (ICL) is obtained from the submucosal layer of the porcine small intestine. ICL grafts provide the necessary mechanical properties for vascular graft applications but, unlike synthetic materials, they are designed to be remodeled by the host tissue. These studies will characterize that remodeling process in a rabbit model. PROPOSED COMMERCIAL APPLICATIONS: Arterial replacement is a common treatment for vascular disease with over 400,000 coronary grafts performed each year in the US. The availability of autografts is becoming increasingly limited as the number and complexity of coronary bypass procedures increase. Conservatively, the potential market for a small diameter, prosthetic vascular grafts would be in excess of 50,000 units per year, or 10% of all vascular grafting procedures in the US.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R43
  • Administering IC
    HL
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
  • Organization Name
    ORGANOGENESIS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    CANTON
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    02021
  • Organization District
    UNITED STATES